<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762589</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-014</org_study_id>
    <nct_id>NCT04762589</nct_id>
  </id_info>
  <brief_title>RT001 in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrotope, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrotope, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess&#xD;
      Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral&#xD;
      Sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty subjects at 4 EU sites will undergo baseline examination, and then be randomized 1:1 to&#xD;
      receive either RT001 or placebo. Repeat visits will occur every 2 months. The final visit&#xD;
      will be at 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo-controlled, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the revised ALS Functional Rating Score (ALSFRS-R) at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in ALSFRS-R will be compared for the RT001 treated group vs placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Death or a Specified State of Disease Progression</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in the composite endpoint will be compared for the RT001 treated group vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in ALSAQ40 will be compared for the RT001 treated group vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SVC</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in SVC will be compared for the RT001 treated group vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity and relationship to study drug of AEs and SAEs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Frequency, severity and relationship to study drug of AEs and SAEs will be compared for the RT001 treated group vs placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>RT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months</description>
    <arm_group_label>RT001</arm_group_label>
    <other_name>di-deuterated linoleic acid ester</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>safflower oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subject with age 20 years to 75 years at the time of signed consent&#xD;
&#xD;
          2. Patients who are defined as &quot;definite ALS,&quot; &quot;probable ALS&quot; or&#xD;
             &quot;probable-laboratory-supported ALS,&quot; met diagnostic criteria revised EL Escorial for&#xD;
             Airlie House.&#xD;
&#xD;
          3. ALSFRS-R &gt; 20&#xD;
&#xD;
          4. Patients who can eat a meal, excrete, or move with oneself alone, and do not need&#xD;
             assistance in everyday life&#xD;
&#xD;
          5. Patients of less than 3 years after the onset of ALS&#xD;
&#xD;
          6. Subject has an identified, reliable, study partner (e.g., caregiver, family member,&#xD;
             social worker, or friend)&#xD;
&#xD;
          7. If patients are duly capable of study consent but are unable to sign by themselves due&#xD;
             to aggravation of disease condition, written informed consent can be obtained from a&#xD;
             legally authorized representative who can sign on behalf of the patients after&#xD;
             confirming the patients' agreement to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with other experimental therapies within the last 30 days prior to&#xD;
             the first dose&#xD;
&#xD;
          2. Previously received treatment with RT001&#xD;
&#xD;
          3. Refusal to discontinue fish oils or other oil-based supplements for the duration of&#xD;
             the study (Screening till last study procedure completed)&#xD;
&#xD;
          4. SVC &lt; 70 at screening&#xD;
&#xD;
          5. Subject has a feeding tube or the need for a feeding tube is anticipated within the&#xD;
             first 24 weeks after enrollment&#xD;
&#xD;
          6. Subject resides at a skilled nursing or dementia care facility, or admission to such a&#xD;
             facility is planned during the study period&#xD;
&#xD;
          7. Evidence of any clinically significant neurological disorder other than ALS&#xD;
&#xD;
          8. The subject has a history of or currently has schizophrenia, schizoaffective disorder&#xD;
             or bipolar disorder according to DSM-V or ICD-10 criteria&#xD;
&#xD;
          9. The subject has a significant pulmonary disorder not attributed to ALS or who require&#xD;
             treatments that might complicate the evaluation of the effect of ALS on respiratory&#xD;
             function&#xD;
&#xD;
         10. Subject has had a significant illness or infection requiring medical intervention in&#xD;
             the past 30 days&#xD;
&#xD;
         11. Female who is breastfeeding or has a positive pregnancy test&#xD;
&#xD;
         12. Male participant or female participant of childbearing potential, who is sexually&#xD;
             active and unwilling/unable to use a medically acceptable and effective double barrier&#xD;
             birth control method throughout the study&#xD;
&#xD;
         13. Unwilling or unable to comply with the requirements of this protocol, including the&#xD;
             presence of any condition (physical, mental, or social) that is likely to affect the&#xD;
             subject's ability to return for visits as scheduled&#xD;
&#xD;
         14. History, within the last 2 years, of alcohol abuse or physical opioid dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard van den Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark G Midei, MD</last_name>
    <phone>+1 (410) 371-5357</phone>
    <email>mark@retrotope.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tartu</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karin Rallmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riga Stradins Universtiy</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viktorija Kenina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard van den Berg</last_name>
    </contact>
    <investigator>
      <last_name>Leonard van den Berg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Ingre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

